Medication Monitor

Generic Name (Trade Name—Company)
November 30, 2011


(generic—Watson; Ranbaxy)
Generic version of Lipitor now available


Management of dyslipidemia; cardiovascular risk reduction

The first generic versions of Pfizer’s blockbuster drug Lipitor were launched today by Watson Pharmaceuticals and Ranbaxy Laboratories, according to news releases on the Watson and FDA websites.

The Watson product is an authorized generic version of the drug, with Pfizer manufacturing and supplying Watson with all dosage strengths of the product. Although Watson will market and distribute the product in the U.S., Pfizer will receive a share of the net sales until November 30, 2016.

Ranbaxy's product is being manufactured by Ohm Laboratories at its New Jersey–based facility. As the first generic approved by FDA, Ranbaxy atorvastatin has a 180-day market exclusivity period. But, barring legal challenges, Pfizer's authorization of the Watson product means that two generic versions are immediately available.

Pfizer is also taking a number of other actions to protect its market share of Lipitor, according to reports in the consumer media